Side effects of cannabis abuse – who is at increased risk of heart failure?

The abuse of cannabis in smoked form has ceased to be solely a neurological issue; it is a matter of utmost cardiological importance. A meta-analysis published in 'Heart' in 2025, involving 432 million participants, showed a 29% increase in the risk of acute coronary syndrome and a 20% increase in the risk of stroke among cannabis users. The results of the 'All of Us' program (Journal of the American Heart Association, 2024) add to this picture with a 34% higher risk of heart failure among daily users. In this text, we show who belongs to high-risk groups, what mechanisms underlie these numbers, what interactions with cardiological drugs are clinically significant, and what the safety profile of CBD looks like in cardiovascular diseases.

What you will find in this guide. Hard population data from 2023-2025 on the relationship between cannabis and heart diseases. Pathophysiological mechanisms: tachycardia, vasoconstriction, oxidative stress, platelet activation. Profile of patients most at risk of cardiological complications. Interactions of cannabinoids with cardiovascular drugs via cytochrome P450. A review of promising but still experimental data on CBD in heart failure and ischemia. Practical tips on when to respond urgently and when to seek a cardiologist immediately. how cannabinoids affect the human body is /how-cbd-and-other-cannabinoids-affect-the-human-body/

Why have cannabis become a cardiological problem of the 21st century?

Cannabis has become a cardiological problem because the number of users is rapidly increasing, and the population of older patients burdened with heart diseases is increasingly turning to medical and recreational marijuana. According to a report from the American Heart Association in 2025, the number of adults using cannabis daily in the USA rose from 0.9% in 2002 to 6.7% in 2022, and in the 65+ age group, it has doubled over the last decade.

The change is dramatic. Until recently, cardiological research focused on tobacco and alcohol. Now cannabinoids are entering the list of major modifiable cardiovascular risk factors. This creates an urgent need to update clinical guidelines, which in most European countries still remain silent on cannabis.

In Poland, the situation is further complicated. The medical marijuana market has been developing since 2017, the popularity of CBD cannabis products is growing, and recreational use, although formally illegal, remains widespread. A cardiology patient may come into contact with cannabis through several pathways simultaneously.

How has the scale of the phenomenon changed over the last decade?

According to the scientific statement from the AHA in 2020 and the update from 2024 (Circulation, 2020), the concentration of THC in marijuana samples confiscated in the USA increased from about 4% in the 90s to over 16% in 2022. In concentrates, it reaches even 80-90%. This means that the modern 'joint' is not comparable to the joint from three decades ago.

At the same time, the percentage of daily users has increased. In the 'All of Us' program, which included 156,999 adults, the proportion of those reporting daily cannabis use was 4%, while an additional 25% reported occasional use. For a cardiologist, these are alarming data.

Citation capsule. The scientific statement from the American Heart Association published in 'Circulation' (2020) indicates that the average THC concentration in marijuana available on the American market increased from 4% in the mid-90s to 16% in 2022, and in concentrates, it reaches 80-90%. This change in the pharmacological profile makes modern cannabis more cardiotoxic than the products on which older literature was based.

Which patient groups must consider the highest risk?

The highest risk of cardiological complications from cannabis concerns patients with diagnosed coronary artery disease, those who have had a myocardial infarction, with arrhythmias, cardiomyopathy, heart failure, and uncontrolled hypertension. An analysis from the Journal of the American College of Cardiology in 2023 on a sample of 33,173 patients after myocardial infarction showed that cannabis users had a 23% higher risk of reinfarction within a year of observation.

The list of risk groups is not academic. Each has a clear pathophysiological mechanism through which cannabinoids, particularly smoke from burned marijuana, can exacerbate clinical conditions. Below, we break them down into practical diagnostic categories.

Coronary artery disease and post-infarction state

Patients with diagnosed coronary artery disease have narrowed epicardial arteries with atherosclerotic plaques. THC induces tachycardia of 20-50% above baseline, increasing the myocardial oxygen demand. At the same time, smoke contains carbon monoxide, which reduces oxygen supply. This pharmacological scissors lead to ischemia, potentially triggering angina or infarction.

A study published in the 'Journal of the American College of Cardiology' (2023) found that cannabis users admitted to the hospital with acute coronary syndrome had significantly higher rates of in-hospital deaths and readmissions within 12 months compared to non-smoking patients.

Arrhythmias and cardiomyopathy

Cannabinoids modulate the autonomic nervous system, affecting the sinoatrial node and atrioventricular conduction. In individuals predisposed to atrial fibrillation, supraventricular tachycardia, or premature ventricular contractions, THC can trigger episodes of arrhythmia. Cases of ventricular fibrillation and sudden cardiac death have been reported in young users (AHA, 2020).

Takotsubo cardiomyopathy, known as 'broken heart syndrome', has been documented as a potential complication of intensive cannabis use. The mechanism involves a catecholamine storm triggered by THC in predisposed individuals.

Hypertension and chronic heart failure

THC causes a biphasic blood pressure response: a short-term increase with tachycardia, followed by orthostatic hypotension. In patients with hypertension treated with beta-blockers or calcium antagonists, this can lead to blood pressure spikes and dizziness. In heart failure, particularly HFrEF (with reduced ejection fraction), increased metabolic demand on the heart is highly undesirable.

Editorial observations indicate that cardiology patients asking about CBD often confuse it with medical marijuana containing THC. Distinguishing between these two categories is of fundamental clinical importance. CBD does not induce tachycardia, THC does.

the difference between CBD and CBG is /cbg-a-cbd-jaka-jest-roznica/

Citation capsule. A study published in the 'Journal of the American College of Cardiology' (2023) on a sample of 33,173 patients after acute coronary syndrome showed that cannabis users had a 23% higher risk of recurrent heart attack during a 12-month follow-up, and the risk of in-hospital death was 11% higher. The mechanism involves THC-induced tachycardia, increased blood pressure, and platelet activation.

What did the 'All of Us' and National Inpatient Sample studies show?

The 'All of Us' (NIH) and National Inpatient Sample (NIS) programs provided two of the most important contemporary population analyses on the impact of cannabis on the cardiovascular system. Both were presented at the AHA Scientific Sessions 2023 and published in the 'Journal of the American Heart Association' and related peer-reviewed journals. The results are consistent regarding the direction of risk.

These two datasets form the foundation of current cardiological guidelines on cannabis use. Both were constructed as prospective and retrospective observational studies, accounting for a wide range of confounding factors (tobacco, alcohol, diabetes, cholesterol, BMI).

The 'All of Us' program and heart failure

'All of Us' is a national NIH program that monitored 156,999 adults without pre-existing heart failure for an average of 45 months. During this period, 2,958 participants (almost 2%) developed heart failure. After adjusting for age, gender, tobacco use, diabetes, hypertension, cholesterol, and obesity, daily cannabis users had a 34% higher risk of HF than those who never used it (JAHA, 2024).

A secondary analysis including coronary artery disease in the model reduced this risk to 27%, suggesting that myocardial ischemia remains the main link between daily cannabis smoking and heart failure. In other words, cannabis is likely not an independent myocardial damaging factor but an accelerator of coronary artery disease, which then leads to HF.

National Inpatient Sample and hospitalizations in the 65+ group

The second study analyzed hospitalizations of adults over 65 with cardiovascular risk factors, namely type 2 diabetes, hypertension, or hypercholesterolemia, who reported not smoking tobacco. A total of 28,535 cannabis users were identified and compared with a control group without use.

• In the cannabis user group, the risk of a serious cardiovascular event during hospitalization was about 20% higher.
• The incidence of heart attacks was 7.6% vs 6.0% in the control group.
• The percentage of hypertension and hypercholesterolemia was also higher among cannabis users.

Meta-analysis 'Heart' 2025: 432 million participants

The largest quantitative meta-analysis to date, published in „Heart” (BMJ, 2025), combined 24 studies with 432 million person-years. The result: a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke, and a 150% increase in the risk of cardiovascular death among individuals with heavy cannabis use. The direction of the effect is maintained in subgroup analyses by age, sex, and geographical region.

The comparison of three key population studies shows convergence of the order of magnitude. Regardless of methodology, cardiovascular risk among daily cannabis smokers increases by 20-35%, and among those with comorbidities, even more clearly.

Citation capsule. The meta-analysis published in „Heart” (BMJ, 2025), encompassing 24 observational studies and over 432 million person-years, demonstrated that cannabis use is associated with a 29% increase in the risk of acute coronary syndrome, a 20% increase in the risk of stroke, and a 2.5-fold increase in the risk of cardiovascular death among heavy users. The authors recommend treating cannabis as a modifiable risk factor in cardiovascular assessment.

What pathophysiological mechanisms underlie the cardiotoxicity of THC?

The cardiotoxicity of THC arises from five interacting mechanisms: sympathetic tachycardia, coronary vasospasm, platelet activation, oxidative stress, and increased carbon monoxide levels in smokers. A review published in „European Heart Journal” (2023) summarizes a decade of pharmacological and clinical research in this area.

The mechanisms operate on different time axes. Acute effects appear within minutes of inhalation. Chronic effects, such as accelerated atherosclerosis, build up over years of daily use. Distinguishing between these two trajectories is clinically significant for patients in acute and chronic states.

Tachycardia and increased oxygen demand

THC stimulates CB1 receptors in the central and peripheral nervous systems, leading to increased sympathetic tone. The effect manifests as an increase in heart rate of 20-100% within 10-30 minutes of inhalation. In individuals with coronary artery disease, where coronary reserve is limited, such an increase in oxygen consumption can trigger segmental ischemia and angina.

Coronary vasoconstriction and endothelial dysfunction

Studies on animal models and experimental human data indicate that THC and some synthetic CB1 agonists can induce vasospasm of coronary vessels. Cases of acute myocardial infarction have been reported in young individuals with normal coronary anatomy, where the only trigger was a high episode of cannabis use.

Endothelial dysfunction, or the inability of vessels to properly vasodilate, is documented in cohorts of chronic users. The mechanism involves oxidative stress, reduced availability of nitric oxide (NO), and activation of inflammatory pathways.

Platelet activation and prothrombotic states

Platelets are equipped with CB1 and CB2 receptors. THC increases their aggregation in in vitro and ex vivo studies. In individuals with atherosclerosis, where plaques are prone to rupture, additional platelet activation can trigger coronary or cerebral thrombosis. This mechanism underlies part of the cases of ischemic stroke in young cannabis users.

Smoke, carbon monoxide, and carboxyhemoglobin

This is the least pharmacological but most brutal mechanism. Smoke from burned marijuana, like tobacco smoke, contains carbon monoxide (CO), which binds to hemoglobin 240 times more strongly than oxygen, forming carboxyhemoglobin. An increase in COHb of 2-4% after a smoking session significantly reduces oxygen supply to the myocardium.

This explains why the route of administration is of fundamental cardiological importance. A patient using CBD oils or vaporizing dry herb has no exposure to CO. A patient smoking a joint, with or without tobacco, does. The difference between these scenarios can be the difference between stable coronary disease and a heart attack.

Citation capsule. The review published in „European Heart Journal” (2023) summarizes five interacting mechanisms of THC cardiotoxicity: sympathetic tachycardia, coronary vasospasm, endothelial dysfunction, platelet activation, and increased carboxyhemoglobin in smokers. The authors call for the inclusion of cannabis in the standard cardiological interview alongside tobacco and alcohol.

What alarm symptoms require immediate action?

Alarm symptoms after cannabis use in individuals with heart diseases include chest pain, significant tachycardia, syncope, resting dyspnea, rhythm disturbances, and sudden dizziness. According to the recommendations of the American College of Cardiology (2024), each of these symptoms in a cardiology patient after cannabis exposure requires immediate assessment in the emergency room or contact with the emergency number.

This is not a rhetoric of excessive caution. Serial cases of myocardial infarction have been reported in individuals in their 20s and 30s, where the only trigger was an intense episode of cannabis use (NEJM, 2019). In older individuals, with a background of atherosclerosis, the risk is many times higher.

Chest pain and angina symptoms

Retrosternal pain, pressure-like, radiating to the left arm, jaw, or back is a classic presentation of myocardial ischemia. After a marijuana smoking episode, pain occurring within 1-4 hours requires immediate evaluation. Any delay increases the area of necrosis. The protocol „time is muscle” applies regardless of the trigger for the heart attack.

Tachycardia, palpitations, and syncope

An increase in heart rate above 120/min, lasting more than an hour, or sudden palpitations unrelated to exertion should prompt an ECG. In individuals suspected of paroxysmal atrial fibrillation, Holter monitoring is recommended.

Syncope after inhaling marijuana, especially in older individuals or those with low baseline blood pressure, may result from orthostatic hypotension or an episode of arrhythmia. Any syncope in this population requires the exclusion of a cardiovascular cause.

Dyspnea and heart failure symptoms

Resting dyspnea, orthopnea, nocturnal dyspnea, or lower limb edema occurring after a period of intense cannabis use may indicate decompensation of heart failure. Patients with diagnosed HF should monitor their weight, saturation, and subjective symptoms for 48-72 hours after each exposure.

Stroke symptoms

Sudden weakness or numbness on one side of the body, drooping of the corner of the mouth, slurred speech, visual disturbances, severe headache. The FAST protocol (Face, Arms, Speech, Time) applies to everyone. The time to thrombolysis or thrombectomy determines neurological prognosis.

how CBD affects sleep and insomnia is /how-cbd-affects-sleep-and-insomnia/

Citation capsule. The recommendations of the American College of Cardiology from 2024 indicate that in patients with cardiovascular diseases after cannabis exposure, each of the following symptoms requires immediate assessment: chest pain lasting more than 20 minutes, tachycardia above 120/min lasting more than an hour, syncope, resting dyspnea, and focal stroke symptoms. Delaying intervention can cost myocardium or brain.

How do cannabis and cardiological drugs interact?

Cannabinoids, including CBD and THC, are primarily metabolized by cytochrome P450 isoenzymes, particularly CYP3A4, CYP2C9, and CYP2C19. A review published in „Clinical Pharmacokinetics” (2023) indicates that CBD is a strong inhibitor of CYP3A4 and CYP2C9, which can raise the concentrations of many cardiovascular drugs by 20-200%. This is not an academic detail; it is a potential life-threatening issue.

The pharmacokinetic interactions of cannabinoids with cardiovascular drugs are an actively researched area. In recent years, a series of case reports and database analyses (FAERS, EudraVigilance) have been published showing the clinical consequences of these interactions.

Anticoagulants: warfarin and DOACs

Warfarin is metabolized by CYP2C9, which is strongly inhibited by CBD. Doubling of INR values has been reported in patients taking warfarin after starting CBD oil, with bleeding requiring transfusions (PMC, 2022). NOACs (rivaroxaban, apixaban, dabigatran) are metabolized by CYP3A4 and P-glycoprotein, also potentially modified by cannabinoids.

Any patient on oral anticoagulation must consult with a cardiologist or hematologist regarding any form of cannabis use before starting. Monitoring INR in the case of warfarin is the minimum; changing therapy is an option.

Statins and CYP3A4

Simvastatin, atorvastatin, and lovastatin are metabolized by CYP3A4. CBD, as an inhibitor of this enzyme, may increase their exposure in plasma, raising the risk of myopathy and rhabdomyolysis. Rosuvastatin and pravastatin have different metabolic pathways and are theoretically safer in this context.

Calcium antagonists and antiarrhythmics

Amlodipine, verapamil, diltiazem are common drugs in the treatment of hypertension and arrhythmias. CBD may increase their concentration by inhibiting CYP3A4, which clinically manifests as decreased blood pressure, bradycardia, or atrioventricular block. Antiarrhythmics such as amiodarone, flecainide, and propafenone also share this metabolic pathway.

Beta-blockers and diuretics

Metoprolol is metabolized by CYP2D6, which CBD has a weaker effect on. Bisoprolol and atenolol are primarily excreted by the kidneys and are largely independent of cannabinoids. Loop diuretics (furosemide, torsemide) and thiazides also have a low risk of metabolic interactions; however, cannabinoids may exacerbate orthostatic hypotension.

Patients often assume that "first-hand" or "natural" CBD oil is safer than a prescription drug. Pharmacokinetics does not care about the label "natural". A CYP3A4 inhibitor is a CYP3A4 inhibitor, regardless of whether it comes from a cannabis extract, grapefruit, or a synthetic drug.

how CBD and other cannabinoids affect the human body is /how-cbd-and-other-cannabinoids-affect-the-human-body/

Citation capsule. The review published in „Clinical Pharmacokinetics” (2023) documents that CBD is a strong inhibitor of CYP3A4 and CYP2C9, increasing the concentrations of warfarin, amiodarone, amlodipine, and simvastatin in plasma by 20-200%. The authors classify the interactions as clinically significant and recommend a cannabinoid history for every patient starting or modifying cardiovascular treatment.

Is medical marijuana safer than recreational?

Medical marijuana is not automatically safer than recreational use in a cardiological context if used in the form of smoking. The concentration of THC, daily dosage, method of administration, and medical supervision are decisive. According to the „CHEST” analysis from 2024, oncology patients smoking medical marijuana had the same exposure to carbon monoxide and carcinogens as recreational users.

The difference between medical and recreational marijuana mainly lies in the control of composition, access to a supervising physician, and the recommendation of a specific route of administration. The THC molecule itself does not change its pharmacology. If a cardiology patient smokes medical flower at home without supervision, the risk is comparable to smoking illegal marijuana.

The role of the route of administration for cardiological safety

The hierarchy of cardiological safety for cannabinoid routes of administration is as follows. The safest are oral forms (oils, capsules) and sublingual forms, which do not introduce carbon monoxide. Vaporization is an intermediate compromise, eliminating most pyrolysis products. Smoking, with or without tobacco, poses the highest risk.

• Oral and sublingual forms. No smoke, no CO, no pyrolysis. Slower pharmacokinetics, peak concentration in 1-3 hours.
• Vaporizing dry herb. A temperature of 180-210 degrees Celsius extracts cannabinoids without burning organic matter, reducing CO exposure by over 90%.
• Smoking a pure joint. Generates tar, CO, and polycyclic aromatic hydrocarbons. Each session raises COHb by 2-5%.
• Smoking with tobacco (spliff). Maximum exposure to carcinogens and CO, with nicotine and cannabinoid effects overlapping on the cardiovascular system.

Medical flower and self-dosing

In the medical marijuana program in Poland, patients receive flower from the pharmacy, with a specific content of THC and CBD, with a doctor's recommendation. However, in practice, many patients adjust the dose themselves, exceeding recommendations. From a cardiological perspective, each additional inhalation increases exposure to CO and the peak concentration of THC.

Editorial observations: cardiology patients using medical marijuana most often benefit when it is limited to vaporization or oral forms, and the daily THC dose is kept below 10 mg. High doses of smoked THC are cardiologically unacceptable in individuals with coronary artery disease.

Citation capsule. The analysis published in „CHEST” (2024) compared exposure to carbon monoxide, tar, and polycyclic aromatic hydrocarbons in oncology patients smoking medical marijuana and recreational users. The results showed that the mere fact of prescribing marijuana as a medication does not change the toxicological profile of the smoke. Risk reduction requires changing the method of administration to vaporization or oral.

What do studies say about the potential cardioprotective effects of CBD?

CBD shows experimental anti-inflammatory, antioxidant, and vasodilatory properties that could theoretically protect the myocardium. However, a systematic review published in „British Journal of Pharmacology” (2023) indicates that despite promising preclinical data, no randomized phase III clinical trial has confirmed the cardioprotective effect of CBD in humans. CBD is not an approved drug for cardiovascular diseases.

This is an important distinction. The media often report results from animal studies or cell lines as ready clinical recommendations. In cardiology, where the stakes are life, we require evidence from randomized controlled trials in humans. Currently, such evidence for CBD in HF, coronary artery disease, or arrhythmias is lacking.

Vasodilation and impact on blood pressure

A randomized pilot study published in „JCI Insight” (2017) showed that a single dose of 600 mg of CBD lowered systolic blood pressure at rest and during mental stress in healthy volunteers. The effect was moderate (5-10 mmHg) and transient. No large clinical trials have yet been conducted in patients with hypertension.

In animal models, CBD exhibits vasodilatory effects through its impact on TRPV1 receptors, PPAR-gamma, and the endocannabinoid system. These mechanisms are consistent with potential hypotensive effects, but clinical translation requires confirmation in phase III studies.

Anti-inflammatory and antioxidant properties of CBD

Inflammation and oxidative stress are key elements in the pathogenesis of atherosclerosis, myocardial infarction, and heart failure. CBD exhibits anti-inflammatory effects by inhibiting pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1 beta) and antioxidant effects by reducing the production of reactive oxygen species.

In experimental models of myocardial infarction, CBD reduced the area of necrosis, improved myocardial contractility, and reduced inflammatory markers. Similar observations have been made in models of doxorubicin-induced cardiomyopathy, myocarditis, and septic stress.

The endocannabinoid system in heart diseases

The endocannabinoid system (ECS) modulates blood pressure, heart rate, myocardial contractility, and the inflammatory response. ECS disorders are documented in heart failure, hypertrophic cardiomyopathy, and post-myocardial remodeling. Studies published in „Pharmaceuticals” (MDPI, 2021) suggest that targeted modulation of the ECS may be a new direction in cardiological pharmacology.

Modulation of CB1 and CB2 elicits different effects. CB1 blockade has cardioprotective effects in heart failure models, while CB2 stimulation reduces inflammation and ischemic damage. CBD, as a CB1 antagonist and allosteric modulator of CB2, theoretically fits into both pathways.

What does a common-sense summary say?

Despite promising preclinical data, current guidelines from the European Society of Cardiology, American Heart Association, and European Medicines Agency (EMA) do not recommend CBD as a drug in cardiovascular diseases. Patients interested in CBD supplementation for general reasons (sleep, anxiety, pain) should consult this with the physician managing their cardiological treatment.

the mechanism of action of CBD in inflammatory states is /researchers-explained-the-mechanism-of-action-of-cbd-in-inflammatory-states/

Citation capsule. The systematic review published in „British Journal of Pharmacology” (2023) analyzes 42 preclinical studies and 7 clinical trials regarding CBD in the context of the cardiovascular system. Despite promising preclinical data, no randomized phase III trial has confirmed the efficacy of CBD in treating coronary artery disease, heart failure, or hypertension. CBD remains a research area, not an approved cardiological drug.

When is immediate cardiological consultation necessary?

Immediate cardiological consultation is necessary before starting cannabis use in any patient with diagnosed cardiovascular disease. According to the position of the European Society of Cardiology (2024), self-medication with cannabinoids in this population is treated as high-risk behavior, comparable to non-compliance with anticoagulant or beta-blocker recommendations.

The list of situations that absolutely require cardiological consultation before starting cannabis use includes specific diagnoses. This is not a theoretical enumeration; it is a list of patients for whom case studies and population studies have shown a significant increase in adverse events after THC exposure.

Diagnoses requiring absolute consultation

• Stable and unstable coronary artery disease. Any form, with or without symptoms, with a history of revascularization (PCI, CABG) or not.
• Post-myocardial infarction state. Applies to all patients after STEMI and NSTEMI, regardless of the time since the event.
• Heart failure with reduced (HFrEF), preserved (HFpEF), or moderately reduced ejection fraction (HFmrEF).
• Cardiomyopathy. Hypertrophic, dilated, arrhythmogenic right ventricle, takotsubo after an episode.
• Arrhythmias. Atrial fibrillation, supraventricular tachycardia, ventricular, higher-degree AV block.
• Poorly controlled hypertension. Blood pressure above 140/90 mmHg despite treatment.
• Patients with implanted devices. Pacemaker, ICD, CRT, post-heart transplant.
• Valvular diseases requiring pharmacotherapy. Aortic stenosis, mitral regurgitation with an indication for monitoring.

What should be discussed during the consultation?

The interview should include the current list of medications, the planned route of cannabis administration, dosage, frequency, and purpose of use. The cardiologist assesses interactions with current pharmacotherapy, the status of the circulatory system, the presence of arrhythmias, and the risk of plaque rupture. They may order a resting ECG, exercise test, or Holter monitoring.

In some cases, the consultation will end with a recommendation to refrain from cannabis. In others, the doctor may accept the oral form of CBD with monitoring of blood pressure and ECG. Every decision should be documented in the patient's record.

Signals requiring hospital admission

If alarm symptoms described earlier (chest pain, tachycardia, dyspnea, syncope, focal symptoms) occur after cannabis use, the cardiology patient should immediately call emergency number 112. In the medical history, it is essential to mention cannabis exposure, as it affects differential diagnosis.

Hiding cannabis use from the doctor in the emergency room is a mistake. This information can significantly change the diagnostic pathway (e.g., coronary vasospasm vs. classic ACS) and treatment choice.

CBD and THC in the treatment of anxiety disorders is /cbd-and-thc-in-the-treatment-of-anxiety-disorders/

Citation capsule. The position of the European Society of Cardiology from 2024 recommends a cannabinoid interview for every cardiology patient, documentation of the route of administration and dosage, and cardiological consultation before starting or modifying the cannabis use regimen. In patients with coronary artery disease, heart failure, arrhythmia, or post-myocardial infarction, the ESC classifies cannabis use as a modifiable risk factor requiring active management.

What does a safe CBD supplementation profile look like for healthy individuals?

A safe CBD supplementation profile for healthy individuals includes oral or sublingual forms, doses of 10-50 mg daily, and awareness of potential drug interactions. A report from the World Health Organization (WHO, 2018) indicates that CBD is well tolerated, has no addictive potential, and does not exhibit typical cardiotoxic effects of THC.

This is an important distinction. Most population studies showing increased cardiovascular risk pertain to smoked marijuana containing THC, not oral CBD oils. The marketing and vague media contribute to the confusion between these two categories.

Cardiologically safe routes of administration

CBD oils, soft capsules, transdermal cosmetics, and oral products such as edibles have the lowest cardiovascular risk profile. They do not generate smoke, do not cause acute peaks in THC concentration, and do not lead to tachycardia of 20-50% as seen with THC inhalation.

For healthy individuals seeking support for stress, sleep disorders, or mild anxiety, CBD oils with a concentration of 5-10% are the standard choice. A typical starting dose is 10-25 mg/day, with the possibility of gradual increase under subjective response control and potential medical consultation.

Popular CBD oils in Polish stores

The following products are available on the Polish market and are broad-spectrum (free of detectable THC) or isolate. All are recommended in sublingual form, which bypasses first-pass hepatic metabolism and provides a bioavailability of about 20-30%.

• CBD SOOL Broad Spectrum Oil 5% (500 mg / 10 ml) priced at 76 PLN. Low concentration, good for beginners. Broad-spectrum product, free of detectable THC.
• CBD SOOL Broad Spectrum Oil 10% (1000 mg / 10 ml) priced at 99 PLN. Medium concentration, for individuals with higher needs.
• Cannova Natural CBG Oil 15% (1500 mg / 10 ml) priced at 240 PLN. CBG oil, the „mother” cannabinoid, exhibiting anti-inflammatory and neuroprotective effects.
• Mars CBD Hemp Herb 9% priced at 59 PLN. Vaporization herb, lower cardiological risk than smoking.

Monitoring during supplementation

Healthy individuals using CBD oils should monitor their blood pressure during the first 2 weeks, especially if taking doses above 50 mg/day. CBD may cause mild blood pressure reduction, which combined with antihypertensive medications can lead to symptomatic hypotension. Other signals to observe include drowsiness, fatigue, and gastrointestinal disturbances.

Individuals taking any chronic medications, especially those metabolized by CYP3A4 and CYP2C9, must consult with a physician before starting CBD. This includes, among others, antiepileptic drugs, anticoagulants, statins, antibiotics, and immunosuppressants.

Citation capsule. A report from the World Health Organization (WHO Expert Committee on Drug Dependence, 2018) reviewed the safety of CBD and concluded that the substance has a good safety profile, has no addictive potential, and does not induce clinically significant tachycardia or vasospasm, as seen with THC. CBD remains a safe supplemental option for healthy individuals, with the caveat of potential drug interactions.

What do the latest meta-analyses from 2024-2025 show?

The latest meta-analyses from 2024-2025 consistently confirm an increased cardiovascular risk among cannabis users, with an effect size of 20-35% for individual endpoints. A key meta-analysis in „Heart” (BMJ, 2025) published alongside an editorial comment sparked a debate about the need to update cardiological guidelines at the European and American levels.

Scientific progress in this field is rapid. In the last three years, more large population studies on cannabis and heart have been published than in the previous two decades combined. This is due to the legalization of recreational marijuana in the USA, Canada, and Germany, which has allowed for transparent research on large cohorts.

Meta-analysis „Heart” (BMJ, 2025)

The authors searched the literature from 2016-2024, including 24 observational studies with 432 million person-years of observation. Endpoints included acute coronary syndromes, strokes, heart failure, sudden cardiac death, and overall cardiovascular mortality. The analysis showed a consistent direction of effect, with moderate strength of association and well-controlled disorders.

• Acute coronary syndrome: HR 1.29 (95% CI 1.12-1.48).
• Stroke: HR 1.20 (95% CI 1.05-1.36).
• Heart failure: HR 1.25 (95% CI 1.10-1.42).
• Cardiovascular death among heavy users: HR 2.50 (95% CI 1.70-3.68).

MESA and CARDIA analysis

The Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) studies provided longitudinal data on the progression of atherosclerosis in cannabis users. In CARDIA, 5,115 young adults were observed for over 25 years. Daily cannabis use correlated with faster progression of coronary artery calcium (CAC) and greater thickness of the carotid intima-media complex.

Molecular studies and biomarkers

The analysis published in „Journal of the American College of Cardiology” (2024) showed that cannabis use correlated with elevated levels of high-sensitivity troponin T, NT-proBNP, and high-sensitivity C-reactive protein. These biomarkers are early indicators of subclinical myocardial damage, low-grade inflammation, and heart failure.

What do meta-analyses NOT show?

Observational studies have limitations. They do not prove causative relationships and may be confounded by unmeasured variables (e.g., stress, lifestyle, alcohol consumption). Randomized clinical trials with cannabis are ethically challenging to design. Therefore, we speak of strong epidemiological signals but not hard experimental evidence.

Despite these limitations, the consistency of the signal across various studies, cohorts, countries, and methodologies allows cardiologists to treat the relationship between cannabis and heart diseases as highly likely causal. Similar reasoning led to the recognition of tobacco as a risk factor in the 1960s, long before randomized studies.

Citation capsule. A meta-analysis published in „Heart” (BMJ, 2025) shows a consistent, moderate increase in cardiovascular risk among cannabis users: 29% for acute coronary syndrome, 20% for stroke, 25% for heart failure, and 150% for cardiovascular death among heavy users. The authors recommend treating cannabis as a modifiable risk factor in cardiology practice, on par with tobacco and alcohol.

What are the practical recommendations for a cardiology patient considering cannabis?

Practical recommendations for a cardiology patient considering cannabis use focus on five principles: consultation with a cardiologist, avoiding smoked forms, preference for CBD over THC, a small starting dose, and monitoring of symptoms. The guidelines from the European Society of Cardiology (2024) and the expert consensus published in „Cardiovascular Research” (2023) provide framework protocols for clinical practice.

This chapter serves as a practical summary of the knowledge from previous sections. The intent is to provide the patient and their physician with a clear checklist that can be applied in the office without the need to sift through the entire text.

Pre-consultation protocol for the patient

1. Step 1. Medical documentation. Prepare a list of cardiological diagnoses, the current list of medications with dosages, results of the last ECG, echocardiography, and biomarkers.
2. Step 2. Purpose of use. Define why you are considering cannabis (sleep, anxiety, pain, appetite). Different purposes lead to different recommendations.
3. Step 3. Route of administration. Prefer oral CBD oils or capsules. Avoid smoking. Vaporization is an intermediate compromise.
4. Step 4. Starting dose. Start with the lowest dose (5-10 mg of CBD daily), gradually increasing every 3-7 days.
5. Step 5. Monitoring. Measure blood pressure and heart rate daily in the first two weeks. Record subjective symptoms.

What should the cardiologist assess?

During the consultation, the cardiologist should assess cardiovascular risk according to current scales (SCORE2, SCORE2-OP), the stability of the underlying disease, the risk of drug interactions, and the patient's readiness for monitoring. If in doubt, they may order 24-hour Holter ECG, blood pressure Holter, or exercise testing before and after a week of CBD supplementation.

Red flags requiring cessation of cannabis

• Unstable coronary artery disease or recent myocardial infarction (up to 6 months).
• Decompensated heart failure (NYHA class III-IV).
• Severe hypertrophic or dilated cardiomyopathy.
• Active high-risk ventricular or atrial arrhythmias.
• Post-implantation of ICD with therapy episodes.
• Severe uncontrolled hypertension (above 180/110 mmHg).
• Polypharmacy with drugs metabolized by CYP3A4 and CYP2C9.

Green light for selected patients

Patients with stabilized hypertension on monotherapy, stable coronary artery disease without complaints, NYHA I-II, without significant polypharmacy, may consider CBD oils in small doses under the supervision of a cardiologist. The purpose should be specific (sleep, anxiety, pain), and effects evaluated after 4-8 weeks.

Should CBD, CBG, and other cannabinoids be used together or separately is /cbg-cbd-and-other-cannabinoids-use-together-or-separately/

Citation capsule. The expert consensus published in „Cardiovascular Research” (2023) defines a five-step protocol for a cardiology patient considering cannabis: mandatory cardiology consultation, preference for oral forms of CBD over smoked THC, a small starting dose of 5-10 mg/day, systematic monitoring of blood pressure and pulse, and re-evaluation after 4-8 weeks. In patients with unstable cardiovascular conditions, cannabis remains a relative or absolute contraindication.

FAQ: Frequently asked questions about cannabis and heart failure

Does daily marijuana smoking really increase the risk of heart failure?

Yes. The „All of Us” program (JAHA, 2024) on a sample of 156,999 adults showed that daily cannabis users had a 34% higher risk of heart failure compared to those who have never used it, after adjusting for age, sex, tobacco use, diabetes, hypertension, and cholesterol. The key mediator is coronary artery disease.

Is CBD safe for individuals with coronary artery disease?

Oral CBD (oils, capsules) has a significantly better cardiological safety profile than smoked marijuana with THC. It does not cause tachycardia or vasospasm typical of THC (WHO, 2018). However, patients with coronary artery disease should consult with a cardiologist regarding CBD use due to interactions with statins, anticoagulants, and calcium antagonists.

What symptoms after marijuana use require calling an ambulance?

Chest pain lasting more than 20 minutes, tachycardia above 120/min lasting more than an hour, syncope, sudden resting dyspnea, focal symptoms (weakness on one side, speech disturbances, facial asymmetry) (ACC, 2024). In the hospital history, it is always essential to mention cannabis exposure, as it affects differential diagnosis.

Is medical marijuana always safer than recreational?

No. The THC molecule itself does not change pharmacology. If a patient smokes medical flower, the exposure to carbon monoxide and carcinogens is the same as with recreational marijuana (CHEST, 2024). The difference lies in the control of composition, physician supervision, and the recommendation of oral or vaporized forms instead of smoking.

Does CBD affect the action of warfarin and NOACs?

Yes. CBD is a strong inhibitor of CYP2C9 (warfarin pathway) and CYP3A4 (rivaroxaban, apixaban pathway). Doubling of INR and bleeding have been reported in patients on warfarin after starting CBD (PMC, 2022). Patients on anticoagulation must consult with their physician regarding CBD use.

How is risk assessed in patients after a heart attack?

Patients after a heart attack have a persistently elevated risk of recurrent events. The JACC study (2023) on a sample of 33,173 patients showed that cannabis users had a 23% higher risk of reinfarction within a year. The cardiological recommendation for this group is to avoid smoked marijuana and consult before any form of cannabis use.

Are there cannabis administration forms that are cardiologically safe?

Relatively cardiologically safe forms are oral (CBD oils, capsules) and sublingual. They do not generate smoke, do not contain carbon monoxide, and do not cause acute peaks in THC concentration. Vaporizing dry herb reduces CO exposure by 90% compared to smoking (NAS, 2017), but it remains a compromise.

Can CBD replace cardiological medications?

No. CBD is not an approved medication for cardiovascular diseases. A systematic review in „British Journal of Pharmacology” (2023) shows that despite promising preclinical data, no phase III randomized study has confirmed the efficacy of CBD in treating coronary artery disease or heart failure. CBD may be a supplement, not a substitute for therapy.

Summary: what to remember from this guide?

The side effects of cannabis abuse in the cardiological context are today one of the best-documented health threats. Data from 2023-2025 are unequivocal: daily smoking of marijuana increases the risk of heart failure by 34% (JAHA, 2024), the risk of acute coronary syndrome by 29%, and the risk of stroke by 20% (Heart BMJ, 2025). The numbers are moderate but consistent, and the pathophysiological mechanisms are well described.

High-risk groups include patients with coronary artery disease, those who have had a myocardial infarction, with arrhythmias, cardiomyopathy, heart failure, and poorly controlled hypertension. For this population, smoked marijuana remains a relative or absolute contraindication. Alarm symptoms, chest pain, tachycardia, dyspnea, syncope, require immediate response.

Interactions with cardiological medications is the second area requiring vigilance. CBD, as an inhibitor of CYP3A4 and CYP2C9, can alter the concentrations of warfarin, statins, calcium antagonists, and antiarrhythmics. Every patient on cardiovascular polypharmacy must consult cannabis with a cardiologist.

Finally, the cardioprotective potential of CBD, while promising in preclinical studies, remains a hypothesis. Until the results of randomized phase III trials, CBD is not a drug in cardiovascular diseases. For healthy individuals, CBD oils in small doses (10-50 mg/day) remain a safe supplemental option, with the caveat of drug interactions.

how CBD affects sleep is /how-cbd-affects-sleep-and-insomnia/

Medical disclaimer. This article is educational and does not replace cardiological consultation. Individuals with coronary artery disease, post-myocardial infarction, heart failure, arrhythmias, cardiomyopathy, hypertension, or post-implantation of a cardiological device (pacemaker, ICD, CRT) must consult cannabis use with their managing cardiologist before starting any form of supplementation. Alarm symptoms (chest pain, tachycardia, syncope, dyspnea) require immediate contact with emergency number 112. Patients on oral anticoagulation (warfarin, rivaroxaban, apixaban, dabigatran), statins, calcium antagonists, antiarrhythmics, and beta-blockers should be aware of significant cannabinoid interactions with cytochrome P450 (mainly CYP3A4 and CYP2C9). CBD products are not drugs, do not diagnose, treat, or prevent cardiovascular diseases. During pregnancy, breastfeeding, and in individuals under 18 years of age, cannabis products are contraindicated.

Author. Michał Waluk, the editorial director of the blog ubucha.pl, specializes in cannabis, cannabinoids, and the pharmacology of medical marijuana. The texts are developed based on peer-reviewed scientific literature (tier 1-3, including PMC, Circulation, JAHA, European Heart Journal, Journal of the American College of Cardiology, Heart BMJ, British Journal of Pharmacology) and official positions of scientific societies (AHA, ACC, ESC, WHO, EMA).